Related Experiment Video

Updated: Aug 6, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Antithrombotic therapy

W L Duvall1

  • 1Zena and Michael A. Weiner Cardiovascular Institute, Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Box 1030, One Gustave L Levy Place, New York, NY 10029, USA. william.duvall@msnyuhealth.org

Current Molecular Medicine
|August 22, 2006
PubMed

Insights

Coronary heart disease (CHD) treatments have advanced significantly since 1980. Antithrombotic therapies targeting coronary thrombosis have greatly reduced mortality and morbidity from acute coronary syndromes.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Coronary heart disease (CHD) is a major cause of death globally.
  • Thrombus formation is a key event in acute myocardial infarction (MI).
  • Antithrombotic therapy has been the standard treatment for CHD for over two decades.

Purpose of the Study:

  • To review the advancements in treating acute coronary syndrome (ACS).
  • To discuss the role of pharmaceutical agents in managing ACS.
  • To highlight the evolving landscape of ACS treatment strategies.

Main Methods:

  • Literature review of studies on antithrombotic therapy for CHD.
  • Analysis of clinical trial data on antiplatelet, antithrombotic, and fibrinolytic agents.
  • Synthesis of current understanding of pharmaceutical interventions in ACS phases.

Main Results:

  • Significant reductions in morbidity and mortality associated with ACS treatments.
  • Demonstration of thrombus as the primary event in acute MI.
  • Development of effective antiplatelet, antithrombotic, and fibrinolytic therapies.

Conclusions:

  • Pharmaceutical agents have substantially improved outcomes for acute coronary syndrome patients.
  • The field of ACS treatment is dynamic, with ongoing research and therapeutic evolution.
  • Effective management of coronary thrombosis remains critical in reducing CHD burden.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...